Aeromonas bacteremia in an elderly immunocompetent patient

BRWMDA:Predicting Microbe-Disease Associations Based on Similarities and Bi-Random Walk on Disease and Microbe Networks

Many current studies have evidenced that microbes play important roles in human diseases. Therefore, discovering the associations between microbes and diseases is beneficial to systematically understanding the mechanisms of diseases, diagnosing, and treating complex diseases. It is well known that finding new potential microbe-disease associations via biological experiments is a time-consuming and expensive process. However, the computation methods can provide an opportunity to effectively predict microbe-disease associations. In recent years, efforts toward predicting microbe-disease associations are not in proportional to the importance of microbes to human diseases. In this study, we develop a method (called BRWMDA) to predict new microbe-disease associations based on similarity and improving bi-random walk on the disease and microbe networks. BRWMDA integrates microbe network, disease network, and known microbe-disease associations into a single network. After calculating the Gaussian Interaction Profile (GIP) kernel similarity of microbes based on known microbe-disease associations, the microbe network is obtained by adjusting the similarity with the logistics function. In addition, the disease network is computed by the similarity network fusion (SNF) method with the symptom-based similarity and the GIP kernel similarity based on known microbe-disease associations. Then, these two networks of microbe and disease are connected by known microbe-disease associations. Based on the assumption that similar microbes are normally associated with similar diseases and vice versa, BRWMDA is employed to predict new potential microbe-disease associations via random walk with different steps on microbe and disease networks, which reasonably uses the similarity of microbe network and disease network. The 5-fold cross validation and Leave One Out Cross Validation (LOOCV) are adopted to assess the prediction performance of our BRWMDA algorithm, as well as other competing methods for comparison. 5-fold cross validation experiments show that BRWMDA obtained the maximum AUC value of 0.9087, which is again superior to other methods of 0.9025(NGRHMDA), 0.8797 (LRLSHMDA), 0.8571 (KATZHMDA), 0.7782 (HGBI), and 0.5629 (NBI). In addition, BRWMDA also outperforms other methods in terms of LOOCV, whose AUC value is 0.9397, which is superior to other methods of 0.9111(NGRHMDA), 0.8909 (LRLSHMDA), 0.8644 (KATZHMDA), 0.7866 (HGBI), and 0.5553 (NBI). Case studies also illustrate that BRWMDA is an effective method to predict microbe-disease associations.

The Outer Membrane Vesicles of Aeromonas hydrophila ATCC® 7966TM: A Proteomic Analysis and Effect on Host Cells

Gram-negative bacteria release outer membrane vesicles (OMVs) into the extracellular environment. OMVs have been studied extensively in bacterial pathogens, however, information related with the composition of Aeromonas hydrophila OMVs is missing. In this study we analyzed the composition of purified OMVs from A. hydrophila ATCC® 7966TM by proteomics. Also we studied the effect of OMVs on human peripheral blood mononuclear cells (PBMCs). Vesicles were grown in agar plates and then purified through ultracentrifugation steps. Purified vesicles showed an average diameter of 90-170 nm. Moreover, 211 unique proteins were found in OMVs from A. hydrophila; some of them are well-known as virulence factors such as: haemolysin Ahh1, RtxA toxin, extracellular lipase, HcpA protein, among others. OMVs from A. hydrophila ATCC® 7966TM induced lymphocyte activation and apoptosis in monocytes, as well as over-expression of pro-inflammatory cytokines. This work contributed to the knowledge of the composition of the vesicles of A. hydrophila ATCC® 7966TM and their interaction with the host cell.

Clinical and Therapeutic Implications of Aeromonas Bacteremia: 14 Years Nation-Wide Experiences in Korea

BACKGROUND

To elucidate the clinical presentation, antimicrobial susceptibility, and prognostic factors of monomicrobial Aeromonas bacteremia in order to determine the most effective optimal therapy.

MATERIALS AND METHODS

We reviewed the medical records of Aeromonas bacteremia patients for the period January 2000 to December 2013 in a retrospective multi-center study.

RESULTS

A total of 336 patient records were reviewed, with 242 having community-acquired bacteremia. The major clinical infections were of the hepatobiliary tract (50.6%) and peritonitis (18.5%), followed by primary bacteremia (17.9%). The infections usually occurred in patients with malignancy (42.3%), hepatic cirrhosis (39.3%), or diabetes mellitus (25.6%). High antimicrobial-resistance rates (15.5% for ceftriaxone, 15.5% for piperacillin/tazobactam) were noted. However, resistance to carbapenem and amikacin was only 9.8% and 3.0%, respectively. Aeromonas hydrophila (58.9%) was the most common pathogen, followed by Aeromonas caviae (30.4%). The severity of A. caviae bacteremia cases were less than that of A. hydrophila or Aeromonas veronii bacteremia (P <0.05). A. hydrophila showed higher antimicrobial resistance than did other Aeromonas species (P <0.05). Patients with hospital-acquired bacteremia were more likely to have severely abnormal laboratory findings and relatively high antimicrobial-resistance rates. Mortality was associated with metastatic cancer, shock, delayed use of appropriate antimicrobial agents, increased prothrombin time, and increased creatinine level (P <0.05).

CONCLUSIONS

Aeromonas species should be considered one of the causative agents of bacteremia in patients with intra-abdominal infections or malignancies. Although ceftriaxone-resistant Aeromonas bacteremia was not statistically related to mortality in this study, it was associated with severe clinical manifestations and laboratory abnormalities. Appropriate antibiotics, including carbapenem, should be administered early, especially in Aeromonas bacteremia patients with shock and impaired renal function.

The genus Aeromonas: taxonomy, pathogenicity, and infection

Over the past decade, the genus Aeromonas has undergone a number of significant changes of practical importance to clinical microbiologists and scientists alike. In parallel with the molecular revolution in microbiology, several new species have been identified on a phylogenetic basis, and the genome of the type species, A. hydrophila ATCC 7966, has been sequenced. In addition to established disease associations, Aeromonas has been shown to be a significant cause of infections associated with natural disasters (hurricanes, tsunamis, and earthquakes) and has been linked to emerging or new illnesses, including near-drowning events, prostatitis, and hemolytic-uremic syndrome. Despite these achievements, issues still remain regarding the role that Aeromonas plays in bacterial gastroenteritis, the extent to which species identification should be attempted in the clinical laboratory, and laboratory reporting of test results from contaminated body sites containing aeromonads. This article provides an extensive review of these topics, in addition to others, such as taxonomic issues, microbial pathogenicity, and antimicrobial resistance markers.